ArticleMolecular therapy. Nucleic acids2020
Improved Cancer Targeting by Multimerizing Aptamers on Nanoscaffolds.
Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Multivalent Aptamers: Contemporary Engineering Strategies and Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Application of multivalent aptamers in tumor diagnosis, analysis and therapy (Review).Oncology letters · 2025Review
- Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker.Pharmaceutics · 2024Article
- Recent Advances and Prospects of Nucleic Acid Therapeutics for Anti-Cancer Therapy.Molecules (Basel, Switzerland) · 2024Review
- Plug-and-play nucleic acid-mediated multimerization of biparatopic nanobodies for molecular imaging.Molecular therapy. Nucleic acids · 2024Article
- Targeted anti-angiogenesis therapy for advanced osteosarcoma.Frontiers in oncology · 2024Review
- Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects.International journal of nanomedicine · 2024Review
- RNA nanostructures for targeted drug delivery and imaging.RNA biology · 2024Review
- MultiplexedNucleic acid therapeutics · 2024Article
- Engineered aptamers for molecular imaging.Chemical science · 2023Review
- Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer.Molecular therapy. Nucleic acids · 2023Article
- Advantages of Material Biofunctionalization Using Nucleic Acid Aptamers in Tissue Engineering and Regenerative Medicine.Molecular biotechnology · 2023Review
- Development and classification of RNA aptamers for therapeutic purposes: an updated review with emphasis on cancer.Molecular and cellular biochemistry · 2023Review
- Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery.Biomaterials research · 2023Review
- Recent Progress on Highly Selective and Sensitive Electrochemical Aptamer-based Sensors.Chemical research in Chinese universities · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamers are short single-stranded oligonucleotides selected to bind with high affinity and specificity to a target. In contrast to antibodies, aptamers can be produced in large-scale
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.